111 related articles for article (PubMed ID: 8477804)
21. Structural evidence for a new IgG1 antibody sequence allele of cattle.
Saini SS; Farrugia W; Muthusamy N; Ramsland PA; Kaushik AK
Scand J Immunol; 2007 Jan; 65(1):32-8. PubMed ID: 17212764
[TBL] [Abstract][Full Text] [Related]
22. Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function.
Isaacs JD; Greenwood J; Waldmann H
J Immunol; 1998 Oct; 161(8):3862-9. PubMed ID: 9780151
[TBL] [Abstract][Full Text] [Related]
23. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.
Newman R; Hariharan K; Reff M; Anderson DR; Braslawsky G; Santoro D; Hanna N; Bugelski PJ; Brigham-Burke M; Crysler C; Gagnon RC; Dal Monte P; Doyle ML; Hensley PC; Reddy MP; Sweet RW; Truneh A
Clin Immunol; 2001 Feb; 98(2):164-74. PubMed ID: 11161972
[TBL] [Abstract][Full Text] [Related]
24. Structural difference in the complement activation site of human IgG1 and IgG3.
Michaelsen TE; Sandlie I; Bratlie DB; Sandin RH; Ihle O
Scand J Immunol; 2009 Dec; 70(6):553-64. PubMed ID: 19906198
[TBL] [Abstract][Full Text] [Related]
25. Antibody dependent cell-mediated cytotoxicity induced by chimeric mouse-human IgG subclasses and IgG3 antibodies with altered hinge region.
Michaelsen TE; Aase A; Norderhaug L; Sandlie I
Mol Immunol; 1992 Mar; 29(3):319-26. PubMed ID: 1557042
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone.
Xia MQ; Tone M; Packman L; Hale G; Waldmann H
Eur J Immunol; 1991 Jul; 21(7):1677-84. PubMed ID: 1711975
[TBL] [Abstract][Full Text] [Related]
27. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.
Tao MH; Morrison SL
J Immunol; 1989 Oct; 143(8):2595-601. PubMed ID: 2507634
[TBL] [Abstract][Full Text] [Related]
28. The production and preclinical characterization of a chimeric anti-breast-cancer antibody, cBC2.
Sutton VR; Burgess J; Pietersz GA; Li WJ; McKenzie IF; Trapani JA
Ther Immunol; 1994 Apr; 1(2):83-93. PubMed ID: 7584487
[TBL] [Abstract][Full Text] [Related]
29. A humanized monovalent CD3 antibody which can activate homologous complement.
Routledge EG; Lloyd I; Gorman SD; Clark M; Waldmann H
Eur J Immunol; 1991 Nov; 21(11):2717-25. PubMed ID: 1834468
[TBL] [Abstract][Full Text] [Related]
30. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
[TBL] [Abstract][Full Text] [Related]
31. Studies on antigen binding by intact and hinge-deleted chimeric antibodies.
Horgan C; Brown K; Pincus SH
J Immunol; 1993 Jun; 150(12):5400-7. PubMed ID: 7685795
[TBL] [Abstract][Full Text] [Related]
32. Separation of cell-dependent antibody (CDA) and inhibitory antibody by protein-A affinity chromatography and the effect of fractions on antibody-dependent cellular cytotoxicity (ADCC).
Sato N; Yabuki Y; Toh K; Ishii Y; Kikuchi K
Immunology; 1979 Mar; 36(3):421-6. PubMed ID: 437836
[TBL] [Abstract][Full Text] [Related]
33. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region.
Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
J Immunol Methods; 2005 Nov; 306(1-2):93-103. PubMed ID: 16236307
[TBL] [Abstract][Full Text] [Related]
34. The natural human IgG anti-F(ab')2 antibody recognizes a conformational IgG1 hinge epitope.
Terness P; Kohl I; Hübener G; Battistutta R; Moroder L; Welschof M; Dufter C; Finger M; Hain C; Jung M
J Immunol; 1995 Jun; 154(12):6446-52. PubMed ID: 7539020
[TBL] [Abstract][Full Text] [Related]
35. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.
Ferrara C; Brünker P; Suter T; Moser S; Püntener U; Umaña P
Biotechnol Bioeng; 2006 Apr; 93(5):851-61. PubMed ID: 16435400
[TBL] [Abstract][Full Text] [Related]
36. Intrachain disulfide bond in the core hinge region of human IgG4.
Bloom JW; Madanat MS; Marriott D; Wong T; Chan SY
Protein Sci; 1997 Feb; 6(2):407-15. PubMed ID: 9041643
[TBL] [Abstract][Full Text] [Related]
37. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells.
Wright A; Morrison SL
J Immunol; 1998 Apr; 160(7):3393-402. PubMed ID: 9531299
[TBL] [Abstract][Full Text] [Related]
38. The mechanism of binding staphylococcal protein A to immunoglobin G does not involve helix unwinding.
Jendeberg L; Tashiro M; Tejero R; Lyons BA; Uhlén M; Montelione GT; Nilsson B
Biochemistry; 1996 Jan; 35(1):22-31. PubMed ID: 8555177
[TBL] [Abstract][Full Text] [Related]
39. Apparent sensitivity of human K lymphocytes to the spatial orientation and organization of target cell-bound antibodies as measured by the efficiency of antibody-dependent cellular cytotoxicity (ADCC).
Christiaansen JE; Burnside SS; Sears DW
J Immunol; 1987 Apr; 138(7):2236-43. PubMed ID: 3549899
[TBL] [Abstract][Full Text] [Related]
40. Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life.
Zuckier LS; Chang CJ; Scharff MD; Morrison SL
Cancer Res; 1998 Sep; 58(17):3905-8. PubMed ID: 9731501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
